STOCK TITAN

MDxHealth (MDXH) director Michael Holder receives 10,000 share option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MDxHealth SA director Michael Holder received a grant of share options as compensation. He was awarded options to purchase 10,000 ordinary shares at an exercise price of $0.76 per share, vesting in full on the date of the annual general shareholders' meeting in the calendar year after the grant. Following this grant, he holds 10,000 share options directly, which expire on May 28, 2036. This is a routine equity incentive award rather than an open-market trade.

Positive

  • None.

Negative

  • None.
Insider Holder Michael
Role null
Type Security Shares Price Value
Grant/Award Share Option 10,000 $0.00 --
Holdings After Transaction: Share Option — 10,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 10,000 options Share options over ordinary shares granted to director
Exercise price $0.76 per share Exercise price for the granted share options
Shares underlying options 10,000 ordinary shares Underlying shares for the granted options
Options after transaction 10,000 options Total derivative holdings following the grant
Option expiry May 28, 2036 Expiration date of granted share options
Share Option financial
"security_title: "Share Option""
Ordinary Shares financial
"underlying_security_title: "Ordinary Shares""
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
grant/award acquisition financial
"transaction_action: "grant/award acquisition""
annual general shareholders' meeting financial
"vest in full on the date of the annual general shareholders' meeting"
A yearly meeting where a company’s shareholders and board of directors come together to review performance, vote on key issues (such as electing directors and approving auditors), and ask questions of management. Think of it like a town-hall or annual check-in where owners can influence how the company is run; outcomes can affect governance, dividend decisions and long-term strategy, all of which can influence the value and risks of an investor’s holdings.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Holder Michael

(Last)(First)(Middle)
CAP BUSINESS CENTER
ZONE INDUSTRIELLE DES HAUTS-SARTS

(Street)
HERSTALBELGIUM4040

(City)(State)(Zip)

BELGIUM

(Country)
2. Issuer Name and Ticker or Trading Symbol
MDxHealth SA [ MDXH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option$0.7606/01/2026A10,000 (1)05/28/2036Ordinary Shares10,000$010,000D
Explanation of Responses:
1. Represents options to purchase 10,000 ordinary shares of the Issuer at a price per share of $0.76 granted on June 1, 2026 which vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year following the calendar year in which the options were granted.
/s/ Joseph Sollee, as attorney-in-fact for Michael Holder06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MDXH director Michael Holder report on this Form 4?

Michael Holder reported receiving a grant of share options, not a market trade. He was awarded options covering 10,000 ordinary shares of MDxHealth SA as compensation, rather than buying or selling existing shares on the open market.

How many MDxHealth (MDXH) share options were granted to Michael Holder?

Michael Holder was granted options over 10,000 ordinary shares of MDxHealth SA. These options represent the right to buy 10,000 shares at a fixed exercise price if the vesting conditions are met and the options are exercised before expiry.

What is the exercise price and expiry date of Michael Holder’s MDXH options?

The share options have an exercise price of $0.76 per ordinary share and expire on May 28, 2036. This means Holder can purchase shares at $0.76 any time after vesting and before that expiration date, subject to plan terms.

When do Michael Holder’s MDxHealth (MDXH) share options vest?

The options vest in full on the date of the annual general shareholders' meeting held in the calendar year following the year of grant. This single vesting date structure means all 10,000 options become exercisable at once after that meeting.

Did Michael Holder buy or sell MDxHealth (MDXH) shares in the market?

No, the Form 4 reflects a grant of share options as compensation, not a market purchase or sale. The transaction code “A” indicates a grant or award, and the price per option at grant was reported as $0.00, typical for equity awards.